• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Al­ny­lam agrees to drop patent law­suit against Mod­er­na over Covid-19 vac­cine

7 months ago
Pharma
Law

J&J dis­con­tin­ues mid-stage dengue study, cit­ing de­pri­or­i­ti­za­tion of com­mu­ni­ca­ble dis­ease work

7 months ago
R&D
Pharma

Ed­i­tas sells fu­ture CRISPR li­cense fees; Plus, news about On­colyt­ics Biotech

7 months ago
News Briefing

Biotech's third quar­ter was rel­a­tive­ly bright — with a few caveats

7 months ago
Financing
Startups

Sanofi sells rare dis­ease drug En­jay­mo to Recor­dati for $825M up­front

7 months ago
Deals
Pharma

Af­ter $14B ex­it, Karuna co-founder finds next bet; Ex-Re­genxbio CEO Ken Mills heads to Tag­works

7 months ago
Peer Review

End of obe­si­ty drug short­age threat­ens pa­tient ac­cess to com­pound­ed shots that Lil­ly calls risky

7 months ago
Pharma
Health Tech

UK gov­ern­ment pro­pos­es phased roll­out of Eli Lil­ly's weight loss drug

7 months ago
Pharma
FDA+

Ex­clu­sive: Re­lay Ther­a­peu­tics cuts an­oth­er 10% of com­pa­ny, cit­ing con­tin­ued stream­lin­ing ef­forts

7 months ago
People
R&D

WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port

7 months ago
Deals
China

FDA's drug cen­ter launch­es new co­or­di­nat­ing body for mod­el­ing and sim­u­la­tion

7 months ago
FDA+

No­vo and Lil­ly out­line plans to mit­i­gate dis­rup­tions from US port strikes

7 months ago
Pharma
Manufacturing

Op­di­vo gets FDA ap­proval for use around lung can­cer surgery, fol­low­ing Keytru­da and Imfinzi

7 months ago
R&D
FDA+

Pfiz­er lays off staff in Ire­land; Bax­ter clos­es NC fa­cil­i­ty due to hur­ri­cane dam­age

7 months ago
Manufacturing

Flag­ship part­ners with key Sin­ga­pore R&D agency as it boosts APAC in­vest­ment

7 months ago
Financing
Startups

FDA lifts par­tial hold on Avid­i­ty’s my­oton­ic dy­s­tro­phy drug; Orum's IPO in South Ko­rea

7 months ago
News Briefing

Eli Lil­ly re­solves short­age for tirzepatide, po­ten­tial­ly end­ing com­pounder­s' run

7 months ago
Pharma

Enara Bio’s $32.5M Se­ries B to sup­port lead dark anti­gen pro­gram for GI can­cers

7 months ago
Financing
R&D

In­vestor Kur­ma Part­ners rais­es €140M for lat­est Eu­rope-fo­cused biotech fund

7 months ago
Financing
Startups

Res­o­lu­tion rais­es $85M to test macrophage ther­a­pies in end-stage liv­er dis­ease

7 months ago
Financing
Cell/Gene Tx

Septer­na files for Nas­daq list­ing as biotech IPOs come to life

7 months ago
Financing
Startups

For next round of IRA price ne­go­ti­a­tions, US says it will meet with com­pa­nies soon­er

7 months ago
Pharma

BioN­Tech opens the hood on its AI am­bi­tions, and they're not just for mR­NA

7 months ago
R&D
AI

As­traZeneca, Ab­b­Vie, PhRMA lose court bat­tle over Louisiana 340B law

7 months ago
Pharma
FDA+
First page Previous page 86878889909192 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times